Integrating Green Chemistry into Clinical Research: Innovative Strategies for Sustainable, Eco-Friendly, and Climate-Responsible Drug Development Across the Pharmaceutical Lifecycle

1.1 Green Chemistry in Clinical Research:

The pharmaceutical industry occupies a singular position at the interface of human health and industrial chemistry. Over the last three decades, advances in medicinal chemistry, formulation science, and clinical trial methodology have dramatically improved therapeutic outcomes. Yet these advances have come with an environmental cost: the manufacture, analysis, and distribution of pharmaceutical agents generate chemical waste, consume energy, and sometimes release residual active pharmaceutical ingredients into the environment. As global attention on sustainability intensifies, there is growing consensus that drug development must reconcile clinical imperatives with environmental stewardship.

Green chemistry-articulated in the twelve principles proposed by Anastas and Warner-provides a conceptual and practical framework for reducing the environmental footprint of chemical processes by minimizing hazardous reagents, maximizing atom economy, and favouring benign solvents and energy-efficient processes. Implementation of green chemistry has produced notable gains in API (active pharmaceutical ingredient) synthesis, catalytic method development, solvent selection, and process intensification [1]. In the Asian research environment, regionally focused journals and research groups have reported numerous practical implementations: green synthetic routes for drug scaffolds [2,3], solvent-minimized analytical methods [4], and plant-based or bio-assisted nanomaterial syntheses intended for pharmaceutical applications (Figure 1). These contributions demonstrate technical feasibility and create a knowledge base that can inform upstream and downstream stages of drug development.

Figure 1: Pharmaceutical applications of Green Chemistry

1.2 Bridging green chemistry with clinical research:

Requires a multipronged approach. First, greener preclinical and GMP-grade manufacturing methods-such as bio-catalysis, solvent replacement, and continuous flow-can be applied during clinical trial material production to reduce waste and hazard while maintaining regulatory compliance. Second, adopting green analytical chemistry for bioanalysis and stability testing (e.g., solvent-reduced chromatographic methods, microextraction techniques, and life-cycle-aware method selection) reduces solvent use and hazardous waste in central laboratories and CROs supporting trials. Third, operational measures in trial conduct-such as decentralized trial elements, digital data capture, and optimized supply chain routing, can cut the carbon and material footprint of multi-centre studies without compromising data quality [5].

This paper argues that integrating green chemistry into the clinical research pipeline is feasible and valuable. By connecting greener synthesis and analytical methods with clinical supply logistics, waste management, and trial design, stakeholders can align clinical research with broader environmental sustainability goals while maintaining the scientific and ethical standards required for human research. To support this argument, we draw on recent methodological reviews and regionally published examples of green chemistry in pharmaceutical contexts, and we identify priority areas for research, regulatory engagement, and implementation (Figure 2) in the Asian clinical research ecosystem.

Figure 2: Pharmaceutical applications of Green Chemistry

Objectives:

This paper aims to:

1. Highlight the relevance of green chemistry principles in shaping sustainable practices within clinical research.
2. Explore opportunities for reducing environmental impact in investigational drug preparation, trial material use, and waste management.
3. Assess the role of regulatory frameworks and operational strategies in facilitating the adoption of sustainable methodologies.
4. Provide recommendations for integrating green chemistry with emerging trends in clinical research, such as decentralized trials and real-world evidence generation.

2. Principles of green chemistry: building a sustainable future

2.1 Highlights

• Green chemistry combines the use of renewable materials, environmentally friendly synthesis methods, and safer solvents to promote sustainability and lessen environmental harm [6].
• The 12 principles of green chemistry provide a framework for developing chemical processes that are both eco-friendly and efficient, aiming to reduce waste, pollution, expenses, and hazards.
• An important example of the effective application of waste prevention in anti-parasitic drugs is the synthesis of tafenoquine, recently approved by the US Food and Drug Administration as the first new single-dose treatment for Plasmodium vivax [7].

2.2 Principles of Green Chemistry [8,9]:

• Prevent waste: Design chemical syntheses to prevent waste instead of treating or cleaning it up.
• Maximize atom economy: Design syntheses to incorporate the maximum amount of starting materials into the final product.
• Design less hazardous chemical syntheses: Use and generate substances with little or no toxicity to humans or the environment.
• Design safer chemicals and products: Chemical products should be fully effective with minimal toxicity.
• Use safer solvents and reaction conditions: Avoid or minimize the use of hazardous solvents and auxiliaries. Use safer alternatives when necessary.
• Increase energy efficiency: Run reactions at ambient temperature and pressure whenever possible.
• Use renewable feed stock: Use raw materials that are renewable rather than depleting.
• Avoid chemical derivatives: Minimize or avoid unnecessary use of blocking or protecting groups and temporary modifications.
• Use catalysts, not stoichiometric reagents: Prefer catalytic reagents that work in small amounts and multiple cycles.
• Design chemicals to degrade after use: Ensure chemical products break down into harmless substances and do not persist in the environment.
• Analyze in real time to prevent pollution: Use in-process monitoring and control to minimize by-product formation.
• Minimize the potential for accidents: Design chemicals and processes to reduce risks such as explosions, fires, and releases.

3. Clinical Research Through Green Chemistry

The pharmaceutical industry faces increasing pressure to align drug development with environmental sustainability goals. Clinical research, often overlooked in this context, has a measurable ecological footprint due to intensive resource consumption, solvent use, energy demands, and waste generation. Embedding green chemistry principles into clinical research is therefore critical for sustainable drug development [10].

3.1 Practical Strategies

3.1.1 Greener Analytical Methods

Replace hazardous organic solvents (e.g., acetonitrile, methanol) with environmentally benign alternatives such as ethanol or isopropanol in 1methods without compromising sensitivity or reproducibility.

3.1.2 Microsampling in Clinical Studies

Adoption of dried blood spot (DBS) and volumetric absorptive micro sampling (VAMS) reduces sample volume, solvent consumption, shipping costs, and cold-chain requirements, lowering both cost and environmental impact.

3.1.3 Decentralized and Digital Clinical Trials

Telemedicine, e-consent, and remote monitoring reduce travel-related emissions and resource usage while improving patient access and retention.

3.1.4 Life Cycle Assessment (LCA) and Metrics

Implementation of Process Mass Intensity (PMI) and E-factor in clinical sample preparation and bio-analysis helps quantify waste and guide greener decision-making across research workflows.

3.1.5 Sustainable Lab Operations

Adopting “green labs” initiatives such as My Green Lab certification and ACT^® ecolabel procurement ensures energy efficiency, waste minimization, and sustainable supply chains in trial laboratories.

3.1.6 Sustainable Trial Logistics

Optimizing clinical trial supply chains through consolidation of shipments, using passive cooling systems, and reducing single-use plastics contributes significantly to carbon footprint reduction.

3.2 Green Approaches to Toxicology and Animal Testing: Industry Perspectives:

3.2.1 Concept and rationale

Green toxicology brings green-chemistry thinking into toxicology and product development: design out hazardous structural features early, use predictive (non-animal) methods to screen for hazards, and apply life-cycle thinking to avoid “regrettable substitutions.” The approach reduces reliance on traditional animal tests while improving human relevance, lowering cost, and decreasing environmental and ethical burdens. Maertens et al. discuss how green toxicology helps avoid replacing one hazardous chemical with another poorly understood alternative (“regrettable substitution”), and why integrating toxicology early in design is essential [10].

3.2.2 Industry drivers and perspectives

Chemical and pharmaceutical companies are motivated to adopt green toxicology by: regulatory pressure to reduce animal use; corporate sustainability and ESG goals;  customer and stakeholder expectations; and economic incentives (faster screening, lower development costs, less liability). Industry sees value in early hazard-avoidance because decisions made in the design phase propagate through scale-up, manufacture, use and disposal, getting it right early prevents downstream harm and costly reformulation. Lackmann et al. outline how eco-toxicological (Figure.3) safety can be embedded into catalyst/chemical development to reduce later-stage problems.

Figure 3: Green Approaches to Toxicology and Animal

Green chemistry in clinical research represents a transformative approach to advancing pharmaceutical sciences while safeguarding environmental and human health. Integrating eco-friendly principles into trial design and drug development ensures reduced ecological impact, enhanced cost-effectiveness, and ethical responsibility toward patients and communities. Thus, green chemistry in clinical research predicts healthier futures today through responsible science, environmental preservation, and sustainable medical progress as shown in Figure.4.

Figure 4: Green chemistry in clinical research predicts healthier future

3.2.3 Impacts of green chemistry

Green chemistry significantly reduces the environmental burden associated with chemical and pharmaceutical activities by emphasizing waste prevention, safer reagents, and energy-efficient processes. The replacement of toxic solvents and reagents with environmentally benign alternatives minimizes contamination of air, water, and soil. Additionally, green chemistry promotes the use of renewable raw materials and catalytic reactions, which decrease reliance on non-renewable resources and reduce greenhouse gas emissions. By designing chemicals that degrade into harmless products, green chemistry also prevents long-term environmental persistence and bioaccumulation. Collectively, these practices contribute to cleaner ecosystems and a lower ecological footprint [11].

• Environment

Green chemistry significantly reduces the environmental burden associated with chemical and pharmaceutical activities by emphasizing waste prevention, safer reagents, and energy-efficient processes. The replacement of toxic solvents and reagents with environmentally benign alternatives minimizes contamination of air, water, and soil. Additionally, green chemistry promotes the use of renewable raw materials and catalytic reactions, which decrease reliance on non-renewable resources and reduce greenhouse gas emissions. By designing chemicals that degrade into harmless products, green chemistry also prevents long-term environmental persistence and bioaccumulation. Collectively, these practices contribute to cleaner ecosystems and a lower ecological footprint.

• Pharmaceutical analysis

In pharmaceutical analysis, green chemistry has transformed traditional analytical practices by encouraging solvent reduction, method miniaturization, and the use of safer chemicals. Techniques such as ultra-high-performance liquid chromatography (UHPLC), micro-scale extraction, and eco-friendly sample preparation significantly reduce solvent consumption and waste generation. Greener analytical methods not only lower environmental impact but also improve laboratory safety by decreasing exposure to toxic chemicals. Furthermore, green analytical approaches often lead to faster analysis, reduced costs, and improved method efficiency, making pharmaceutical quality control and bioanalysis more sustainable and economical.

The chosen method, reagents, accessories, personnel qualification, time to evaluate the quality of a product are part of the ecologically correct thinking, (Figure 5).

Figure 5: The pentagon of ecologically correct thinking.

• Population

Green chemistry positively influences public health by reducing human exposure to hazardous chemicals throughout the pharmaceutical lifecycle. Safer manufacturing processes and cleaner environments result in improved air and water quality, which directly benefits community health. In addition, medicines produced using green principles tend to contain fewer toxic impurities, enhancing their safety profile. Workers in chemical and pharmaceutical industries also experience improved occupational safety due to reduced handling of dangerous substances. Overall, green chemistry supports healthier living conditions and enhances quality of life.

• Company

For pharmaceutical companies, adopting green chemistry provides both environmental and economic advantages. Reduced solvent use, lower waste generation, and energy-efficient processes translate into significant cost savings in raw materials, waste treatment, and energy consumption. Green practices also facilitate compliance with increasingly strict environmental regulations and strengthen corporate social responsibility. Moreover, companies that invest in sustainable technologies gain a competitive advantage by improving their public image and meeting growing market demand for environmentally responsible products.

• Future

Green chemistry plays a critical role in shaping the future of sustainable pharmaceutical development. As global emphasis on climate change mitigation increases, green chemistry will drive innovation toward cleaner technologies and circular economy models. The integration of green chemistry with digital tools, automation, and artificial intelligence will further optimize sustainable processes. In the long term, widespread adoption of green chemistry principles will enable the pharmaceutical industry to meet healthcare needs while minimizing environmental impact, ensuring a sustainable and resilient future for generations to come [12].

3.3 Greenness Assessment Tools and Chromatographic Green Analytical Tools

3.3.1 National environmental methods index (NEMI)

A very simple, visual checklist/pictogram originally from the US EPA that flags whether an analytical method meets four basic “green” criteria. the pictogram is split into four small quadrants (each representing one environmental/health criterion). If the method passes a criterion that quadrant is shaded green; if not it’s blank or red [13].

3.3.2 Raynie and driver tool (Modified NEMI)

An improved, more informative version of the NEMI pictogram proposed by Raynie & Driver-it keeps the pictorial approach but adds nuance and some quantitative elements. Retains quadrant-style visuals but replaces strict pass/fail with graded or annotated indicators and may include additional criteria [13] (e.g., solvent volume, hazard classes).

Output: pictogram + short annotations or graded shading so you see not just pass/fail but how green each part is.

3.3.3 Analytical eco-scale/eco-scale assessment (AES/ESA)

A numeric scoring system where a perfect method starts at 100 and penalty points are subtracted for environmental/health impacts [13]. Higher final scores = greener. Assign penalty points for problematic aspects (harmful reagents, large solvent volumes, energy use, hazardous conditions, waste). Subtract penalties from 100 → final eco-scale score. Typical guidance: >75 = excellent, 50–75 = acceptable, <50 = poor (note: cutoffs vary by publication).

Output: a single number (0–100) plus a list of penalty contributors.

3.3.4 Green analytical procedure index (GAPI)

A visual, multi-segment pentagon/pictogram that evaluates the entire analytical workflow across several stages (sample, reagents, instrumentation, energy, waste, etc.). Each part of the procedure (sample collection, sample prep, reagents, instrumentation, throughput, waste) is represented as a segment or sub-segment and color-coded: green (good), yellow (moderate), red (poor). The full pictogram gives a fingerprint of greenness across the workflow.

Output: a colored multi-segment pictogram-easy visual fingerprint showing strengths/weaknesses.

3.3.5 Complementary green analytical procedure index (ComplexGAPI)

An expanded version of GAPI that adds deeper granularity (more subsegments, extra criteria), often called ComplexGAPI or Complementary GAPI.

Same color-coded pictogram idea but with more boxes/subsegments (e.g., separate evaluation of solvent type, volumes, energy consumption, waste management, sample throughput).

Output: more detailed multi-box pictogram (denser visual).

3.3.6 Modified GAPI (MoGAPI) and ComplexMoGAPI

Community adaptations of GAPI to suit particular needs (e.g., specific types of analyses, sample-prep heavy workflows)-MoGAPI simplifies, ComplexMoGAPI adds depth. Same philosophy-color-coded segments-but with modified criteria, weighting, or segment definitions to better reflect the method class (e.g., LC-MS bioanalysis vs synthetic chemistry).

Output: pictograms tuned to your field.

3.3.7 Analytical GREEnness metric (AGREE)

A modern, quantitative tool that maps an analytical method against the 12 Principles of Green Analytical Chemistry and produces a single score plus a visual wheel. Each of the 12 principles is scored (0–1) and plotted on a circular wheel; an overall composite greenness score (between 0 and 1 or presented as percentage) summarizes the method’s greenness. The wheel shows which principles are weak or strong.

Output: a circular “radar/wheel” graphic + an aggregated numeric score.

3.3.8 Analytical GREEnness metric for sample preparation (AGREEprep)

An AGREE-style metric specialized for the sample preparation step. Sample prep is often the biggest source of solvent/waste in bioanalysis, so AGREEprep focuses there. Similar circular scoring focused on sample-prep principles (solvent volumes, solvent hazard, miniaturization, automation, energy, cleanup efficiency). Gives a wheel + numeric score.

Additional prospects exist for the application of in silico modeling techniques alongside practical strategies such as substance grouping and the use of toxicological threshold values.

Accordingly, methodologies like read-across and category formation, extensively outlined for conventional chemicals by the OECD and ECHA should likewise be adapted and implemented for the safety evaluation of nanomaterials [14].

Output: wheel + score specifically for sample prep.

3.3.9 Analytical method greenness score (AMGS)

A scoring approach that produces a single greenness score for an analytical method (some versions weight factors differently).
Combine several criteria (reagent hazards, solvent volume, energy, waste, throughput) into a composite score; calculation specifics vary by AMGS implementation.

Output: numeric score plus breakdown by contributors.

3.3.10 Ultra-high-performance liquid chromatography (UHPLC)

UHPLC operates at higher pressures using smaller particle columns, which leads to faster separations, better resolution, and significantly lower solvent usage per analysis. When coupled with mass spectrometry (UHPLC-MS/MS), it provides high sensitivity and selectivity while adhering to green principles by using eco-friendly mobile phases such as water with low concentrations of formic acid.

3.3.11 Microextraction-Based Green Analytical Tools

Microextraction techniques are considered one of the most effective green analytical tools because they significantly reduce solvent usage and sample volume. Unlike conventional extraction methods that require large amounts of organic solvents, microextraction approaches operate at micro- or nano-scale, making them environmentally friendly, cost-effective, and safer for analysts.

These techniques minimize chemical waste generation and energy consumption while maintaining high extraction efficiency. Their simplicity and compatibility with chromatographic systems make them ideal for pharmaceutical and bioanalytical applications, particularly when working with limited sample volumes [15,23].

3.3.12 Sensor-Based Green Analytical Tools

Sensor-based analytical tools represent a modern and sustainable approach to chemical detection. These devices convert chemical information into measurable signals and often operate with minimal reagents and energy input [15,23].

Sensors enable on-site, real-time analysis, reducing the need for sample transportation, extensive laboratory infrastructure, and solvent-based methods. This significantly lowers the environmental footprint of analytical monitoring.

Types of Green Sensors

• Electrochemical sensors
• Optical sensors
• Biosensors
• Nanomaterial-based sensors

Microextraction-based, spectroscopic, and sensor-based green analytical tools collectively demonstrate how analytical performance and environmental sustainability can be achieved simultaneously. Their integration into pharmaceutical and bioanalytical workflows supports regulatory compliance, reduces ecological burden, and aligns analytical science with global sustainability goals.

4. Solvents and solvent selection

• Solvents constitute the largest proportion of material input in Active Pharmaceutical Ingredient (API) production, often representing more than 80% of the total material usage. In addition to their high material demand, solvents significantly influence the environmental footprint of pharmaceutical manufacturing, accounting for nearly 60% of overall energy consumption and approximately 50% of post-treatment greenhouse gas emissions [16-18].
• Consequently, solvent selection has become a critical component of sustainable process development. To guide more responsible choices, several organizations-including GSK, Pfizer, the Pharmaceutical Roundtable, and academic research groups have developed solvent selection frameworks [18].
• GSK’s methodology evaluates solvents across multiple dimensions such as health impact, safety considerations, and life cycle assessment (LCA). These criteria are translated into a color-coded scoring system that helps chemists quickly identify preferred, acceptable, or undesirable solvents [19].
• In contrast, Pfizer employs a similarly comprehensive multi-criteria evaluation process but communicates the results in a simplified format that is more practical for routine use in medicinal chemistry laboratories. This streamlined guide has reportedly led to substantial reductions in the use of hazardous solvents, including a near-elimination of chloroform and di-isopropyl ether in certain applications [20].
• Pfizer has also proposed alternative recommendations for solvents categorized as highly undesirable [21] as shown in (Figure 6).
• However, replacing dipolar aprotic solvents such as dimethylacetamide (DMAc), dimethylformamide (DMF), and N-methylpyrrolidinone (NMP) remains particularly challenging. These solvents are subject to strict regulatory scrutiny, especially within the European Union, due to their reproductive toxicity concerns.
• Despite these hazards, they remain widely used because of their excellent solvating ability in metal-catalysed cross-coupling and nucleophilic substitution reactions. In many cases, they are uniquely capable of dissolving highly polar compounds or salts that are otherwise difficult to process. Among these, NMP is often favoured in practice due to its comparatively lower volatility, which reduces the risk of occupational exposure, although it shares similar toxicological concerns with DMAc and DMF.

Figure 6. The Pfizer solvent selection guide

5. Benefits (what we actually gain)

1. 1. Lower greenhouse-gas emissions (from less shipping, less energy use, less solvent production/disposal).
   2. Lower operating costs (less solvent purchase/disposal, simpler logistics).
   3. Faster decisions and safer processes (catalysis/biocatalysis and flow often simplify operations).
   4. Stronger regulatory and stakeholder alignment (supports ESG reporting and reduces regulatory risk). Evidence from studies quantifying trial footprints shows measurable reductions possible when these interventions are applied.
   5. Global Cooperation in Green Chemistry: Over time, several collective organizations have been established to represent and advance the shared interests of pharmaceutical companies. Notable examples include Pharmaceutical Research and Manufacturers of America and European Federation of Pharmaceutical Industries and Associations, both of which advocate for industry development, innovation, and policy engagement at regional and international levels. In 2005, a dedicated initiative was launched under the ACS Green Chemistry Institute to encourage the adoption of green chemistry principles within the pharmaceutical sector. This initiative, known as the Pharmaceutical Roundtable of the ACS Green Chemistry Institute, was designed with a strong technical orientation rather than a policy-driven agenda. Its primary objective has been to promote collaboration among companies on pre-competitive scientific challenges, enabling shared progress in implementing environmentally sustainable practices across the industry [18,20].
   6. By April 2009, participation in the Roundtable included ten global pharmaceutical corporations: AstraZeneca, Boehringer Mannheim, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Merck & Co., Novartis, Pfizer, Schering-Plough, and Wyeth. In addition, two technology-focused organizations—Codexis and DSM—were also members, contributing technical expertise and innovation capabilities [18].
   7. White Analytical Chemistry (WAC) represents an advanced stage in the evolution of sustainable analytical chemistry. It builds upon the foundation of Green Analytical Chemistry (GAC) by extending the evaluation beyond environmental considerations to include analytical performance and real-world applicability. While GAC primarily focuses on minimizing environmental harm, WAC adopts a more comprehensive approach that balances analytical reliability, ecological responsibility, and practical factors such as cost efficiency and ease of implementation. This integrated philosophy is visually represented in WAC through the Red–Green–Blue (RGB) color model (Figure 7), where each color reflects a key dimension of analytical quality [22].

Figure 7: Integrated philosophy is visually represented in WAC through the Red–Green–Blue (RGB) color model

6. Challenges and limitations (practical realities)

4. 1. Validation and regulatory review are needed for method or sampling changes -this requires time and resources.
   2. Applicability domain: not every chemical or analytical method can immediately use greener solvents or microsampling; scientific validation is essential.
   3. Up-front R&D costs: enzyme engineering or flow equipment require initial investment.
   4. Data gaps: LCA and standardized emission factors are needed to compare options reliably; boundaries must be reported transparently.
5. Practical final message

Making clinical research climate-responsible is practical and evidence-based. Start by measuring (PMI, CO?e), pick a few high-impact pilots (microsampling, ethanol HPLC, solvent swaps, small biocatalysis/flow pilots), validate thoroughly, and then scale as illustrated in (Figure 8). Over time, these steps reduce environmental impact, lower cost and risk, and help pharma meet sustainability commitments while preserving scientific quality and patient safety.

Figure 8: Green Analytical Chemistry Approach in preserving scientific quality and patient safety